Sign up Australia
Proactive Investors - Run By Investors For Investors

Cellmid secures second US partner to sell évolis hair growth products

The partnership further advances the company's global expansion and growth.
evolis hair growth products
The company recently completed a 20:1 consolidation of its shares

Cellmid Limited (ASX:CDY) has secured its second premium retail partner in the US, Soft Surroundings.

Soft Surroundings owns 59 stores across the US and will sell Cellmid’s évolis® Professional product range.

Soft Surroundings also has a strong online presence

Headquartered in St. Louis, Soft Surroundings is a lifestyle brand and retailer of women’s beauty products, home and apparel with a fast-growing e-commerce platform.

Soft Surroundings positions itself as a luxury lifestyle brand for busy women of all ages.

Maria Halasz, chief executive, said: “Soft Surroundings has grown remarkably during a challenging period for retailers due to impeccable customer service.

“We look forward to building a strong relationship with their customer base in 2018 and beyond.”

READ: Cellmid makes move to sell hair loss products into China

The agreement is the second premium retail relationship for Cellmid’s évolis® Professional product range, after signing the agreement with Neiman Marcus in August 2017.

It is a key milestone in the company’s US distribution strategy.

Targeting the $14.7 billion prestige hair market

Cellmid’s consumer health subsidiary Advangen currently generates all of the company’s revenue.

The consumer health segment currently sells hair growth products in Australia, Japan and the U.S, which were developed using FGF5 related intellectual property.

During the recent September quarter, the consumer health segment achieves sales of $1.03 million, up 4% on the prior corresponding quarter.

Cellmid is targeting the prestige hair care market, which is expected to reach global sales of $14.7 billion annually by 2021.

View full CDY profile View Profile

Cellmid Ltd Timeline

Related Articles

scientist with vial
August 09 2018
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology
scientist in lab
September 11 2018
The phase 1b trial of Silence’s lead candidate, SLN124, a treatment for a rare blood disorder, is scheduled to begin in the second half of 2019
July 26 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use